Check out UCSF/Affiliate's participation in CROI 2023

February 16, 2023
CFAR and ARI Special Update
UCSF and the UCSF CFAR affiliate sites have an impressing showing at CROI this year! For us to support each other and to be aware of the great work being done here, we have listed the oral, themed discussion and posters led by UCSF or affiliate investigators below. 
Please contact Cesar Cadabes if we have missed any presentations and great work, UCSF!
 
Pre-Conference Sessions/Opening Session - Sunday, February 19, 2023
Date: Sunday, 2/19
Session: Scott M. Hammer Workshop for New Investigators and Trainees
Talk title: ADVANCES IN HIV TREATMENT STRATEGIES
Location: Flex A (Level 2)
Talk time: 8:30am-12:30pm PT
Speaker: Monica Gandhi, UCSF
 
Date: Sunday, 2/19
Session: Workshop-02 FRONTIERS IN LABORATORY TECHNOLOGIES
Talk title: SINGLE-CELL ANALYSIS OF THE RNA, PROTEIN, AND GLYCAN FEATURES OF HIV-INFECTED CELLS
Location: Ballroom 2 (Level 5)
Time: 1:30-3:30pm PT
Speaker: Nadia Roan, Gladstone Institutes
 
Date: Sunday, 2/19
Session: Workshop-04 CLINICAL TRIAL DESIGN AND ANALYSIS
Location: Ballroom 3 (Level 5)
Time: 1:30-3:30pm PT
Moderator: Susan Buchbinder, SFDPH
 
Date: Sunday, 2/19
Session: OPENING-01 OPENING SESSION
Talk Title: INTRODUCTION OF THE N'GALY-MANN LECTURE
Location: Flex C (Level 2)
Time: 5:00-7:00pm PT
Moderator: Diane Havlir, UCSF
 
Plenaries/Symposia - Tuesday, February 21, 2023
Date: Tuesday, 2/21
Session: Symposium-05 COVID-19: WHERE ARE WE NOW?
Talk Title: WHAT WE KNOW NOW ABOUT LONG COVID SYNDROMES
Location: Flex A (Level 2)
Time: 4:00-5:30pm PT
Presenter: Michael Peluso, UCSF
 
Date: Tuesday, 2/21
Session: SPECIAL SESSION-1 RESULTS FROM THE MOSAICO HIV VACCINE TRIAL AND FUTURE DIRECTIONS FOR HIV VACCINES
Talk Title: OVERVIEW OF THE MOSAICO HIV VACCINE TRIAL
Location: Flex A (Level 2)
Time: 5:40-6:00pm PT
Presenter/Moderator: Susan Buchbinder, SFDPH
 
Plenaries/Symposia - Wednesday, February 22, 2023
Date: Wednesday, 2/22
Session: PLENARY-03 WEDNESDAY PLENARY SESSION
Talk Title: CROI PROGRAM COMMITTEE VICE CHAIR WELCOME TO WEDNESDAY TRIAL
Location: Flex C (Level 2)
Time: 8:30-9:30am PT
Presenter: Diane Havlir, UCSF
 
Date: Wednesday, 2/22
Session: SPECIAL SESSION-2 SPECIAL SESSION ON THE MPOX VIRUS OUTBREAK
Talk Title: CROI PROGRAM COMMITTEE VICE CHAIR WELCOME TO WEDNESDAY TRIAL
Location: Ballroom 1 (Level 5)
Time: 12:15-1:15pm PT
Moderator: Diane Havlir, UCSF
 
Oral Abstracts & Themed Discussions
Date: Monday, 2/20
Session: Oral Abstract Session-02 TB AND HEPATITIS
Location: Ballroom 1 (Level 5)
Time: 10:00am-12:00pm PT
  • OA 112: RCT OF ECONOMIC INCENTIVES FOR REDUCED ALCOHOL USE AND INH ADHERENCE AMONG PWH
    • Presenter: Gabriel Chamie, UCSF
    • Time: 10:29-11:00am PT
 
Date: Monday, 2/20
Session: Oral Abstract Session-03 HIV AND STI PREVENTION: NEW TOOLS AND APPROACHES
Location: Flex C (Level 2)
Time: 10:00am-12:00pm PT
  • OA 120: DOXYPEP&ANTIMICROBIAL RESISTANCE INN. GONORRHOEAE, COMMENSAL NEISSERIA & S. AUREUS
    • Presenter: Annie Luetkemeyer, UCSF
    • Time: 10:21-10:28am PT
 
Date: Monday, 2/20
Session: Themed Discussion-03 PREDICTORS OF TB TREATMENT OUTCOMES
Location: Ballroom 1 (Level 5)
Time: 1:30-2:30pm PT
  • TD 740: TB OUTCOMES IN PEOPLE LIVING WITH HIV: AN INTEGRATIVE DATA ANALYSIS OF PHASE 3 TRIALS
    • Presenter: Rob van Wijk, UCSF
    • Time: 1:35-1:39pm PT
Date: Monday, 2/20
Session: Themed Discussion-05 NEW INSIGHTS THROUGH RECENCY TESTING
Location: Flex A (Level 2)
Time: 1:30-2:30pm PT
Moderator: George Rutherford, UCSF
 
Date: Tuesday, 2/21
Session: Oral Abstract Session-08 ALL MODES LEAD TO PrEP
Location: Ballroom 3 (Level 5)
Time: 10:00am-12:00pm PT
  • OA 161: CABOTEGRAVIR FOR HIV PrEP IN US BLACK MEN AND TRANSGENDERWOMEN WHO HAVE SEX WITH MEN
    • Presenter: Hyman Scott, SFDPH
    • Time: 10:21-10:28am PT
 
Date: Tuesday, 2/21
Session: Oral Abstract Session-09 LATE-BREAKING CLINICAL STUDIES ON COVID-19 AND MPOX
Location: Flex C (Level 2)
Time: 10:00am-12:00pm PT
Moderator: Annie Luetkemeyer, UCSF
 
Date: Tuesday, 2/21
Session: Themed Discussion-08 LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING?
Location: Flex C (Level 2)
Time: 1:30-2:30pm PT
  • TD 518: HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION
    • Presenter: Monica Gandhi, UCSF
    • Time: 1:45-2:30pm PT
 
Date: Wednesday, 2/22
Session: Oral Abstract Session-11 NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS OF HIV AND SARS-CoV-2
Location: Ballroom 2 (Level 5)
Time: 10:00am-12:00pm PT
  • OA 183: SEX MODIFIES THE ASSOCIATION OF AGE AND VIREMIA WITH STROKE RISK IN HIV
    • Presenter: Felicia Chow, UCSF
    • Time: 10:05-10:12am PT
 
Date: Wednesday, 2/22
Session: Oral Abstract Session-13 OPTIMIZING THE HIV TREATMENT CASCADE
Location: Flex A (Level 2)
Time: 10:00am-12:00pm PT
  • OA 204: URINE TENOFOVIR LEVELS PREDICT VIRAL SUPPRESSION IN PATIENTS ON TENOFOVIR ALAFENAMIDE
    • Presenter: Kelly Johnson, UCSF
    • Time: 11:08-11:15am PT
 
Date: Wednesday, 2/22
Session: Oral Abstract Session-14 EPIDEMIOLOGY AND PREVENTION OF MPOX AND SARS-CoV-2
Location: Flex C (Level 2)
Time: 10:00am-12:00pm PT
  • OA 209: HOUSEHOLD TRANSMISSION OF MONKEYPOX TO CHILDREN AND ADOLESCENTS
    • Presenter: Darpun Sachdev, SFDPH
    • Time: 10:21am-10:28am PT
Date: Wednesday, 2/22
Session: Themed Discussion-10 CELLULAR IMMUNE CONTROL OF HIV
Location: Ballroom 2 (Level 5)
Time: 1:30-2:30pm PT
  • TD 337: NK CELL BIOMARKERS THAT PREDICT TIME-TO-REBOUND IN HIV+ INDIVIDUALS UNDERGOING ATI
    • Presenter: Ashley George, Gladstone Institutes
    • Time: 1:55-2:30pm PT
 
Date: Wednesday, 2/22
Session: Themed Discussion-11 WEIGHT GAIN: DOES WHAT GOES UP ALWAYS COME DOWN?
Location: Ballroom 1 (Level 5)
Time: 1:30-2:30pm PT
Moderator: Peter Hunt, UCSF
 
Date: Wednesday, 2/22
Session: Themed Discussion-13 PRECLINICAL STUDIES OF NEW PREVENTION INTERVENTIONS
Location: Ballroom 3 (Level 5)
Time: 1:30-2:30pm PT
Moderator: Ariane van der Straten, UCSF
 
Poster Sessions
Date: Monday, 2/20
Time: 2:30-4:00pm PT
 
Session: Poster Session-B6 SARS-CoV-2 PATHOGENESIS
Title: PS 273: DIFFERENTIAL ASSOCIATION OF CYTOMEGALOVIRUS WITH ACUTE AND POST-ACUTE COVID-19
Presenter: Michael Peluso, UCSF
 
Session: Poster Session- D5 NK CELLS, NEUTROPHILS, AND B CELLS
Title: PS 337: NK CELL BIOMARKERS THAT PREDICT TIME-TO-REBOUND IN HIV+ INDIVIDUALS UNDERGOING ATI
Presenter: Ashley George, Gladstone Institutes
 
Session: Poster Session- D6 SARS-CoV-2 IMMUNOPATHOGENESIS
Title: PS 343: POLYFUNCTIONAL SARS-CoV-2-SPECIFIC T CELLS PERSIST IN TISSUE OF COVID19 CONVALESCENTS
Presenter: Kyrlia Young, Gladstone Institutes
 
Session: Poster Session- D6 SARS-CoV-2 IMMUNOPATHOGENESIS
Title: PS 346: UNIQUE DIFFERENTIATION AND HOMING FEATURES OF T CELLS IN INDIVIDUALS WITH LONG COVID
Presenter: Kailin Yin, Gladstone Institutes
 
Session: Poster Session- E1 CONTROLLERS AND POSTTREATMENT CONTROLLERS
Title: PS 380: CD103 EXPRESSION ON CD8 TCELLS PREDICTS LONGER TIME REBOUND OF HIV AFTER ATI
Presenter: Tongcui Ma, Gladstone Institutes
 
Session: Poster Session - CONTROLLERS AND POSTTREATMENT CONTROLLERS
Title: PS 381: THE CIRCULATING CELL-FREE DNA METHYLOME PREDICTS HIV POST-TREATMENT CONTROL
Presenter: Akshay Gala, Vitalant Research Institute
 
Session: Poster Session- E7, MECHANISMS OF HIV LATENCY
Title: PS 439: A NUCLEOSOMAL MODIFICATION COMPLEX FOR SILENCING HIV
Presenter: Zichong Li, Gladstone
 
Session: Poster Session- E7 MECHANISMS OF HIV LATENCY
Title: PS 448: INTERLEUKIN-2-INDUCIBLE T-CELL KINASE (ITK) INHIBITION PREVENTS HIV LATENCY REVERSAL
Presenter: Prerna Dabral, Vitalant Research Institute
 
Session: Poster Session- H5 NEW AGENTS FOR TREATMENT OF SARS-CoV-2 AND RELATED VIRUSES
Title: PS 549: TARGETING THE HOST-VIRUS INTERFACE TO BLOCK SARS-CoV-2 ASSEMBLY IN AIRWAY CELLS
Presenter: Li Du, Vitalant Research Institute
 
Session: Poster Session- O1 PREDICTORS OF TB TREATMENT OUTCOMES
Title: PS 740: TB OUTCOMES IN PEOPLE LIVING WITH HIV: AN INTEGRATIVE DATA ANALYSIS OF PHASE 3 TRIALS
Presenter: Rob van Wijk, UCSF
 
Session: Poster Session- O1 PREDICTORS OF TB TREATMENT OUTCOMES
Title: PS 743: ISONIAZID TOXICITY AMONG PWH WITH LATENT TB WHO CONSUME ALCOHOL: A SINGLE ARM TRIAL
Presenter: Judith Hanh, UCSF
 
Session: Poster Session- Y02 MODELS TO ACHIEVE VIRAL LOAD SUPPRESSION
Title: PS 1038: A LOW-COST, RAPID URINETEST FORTFV INCREASES ART ADHERENCE AND VIRAL SUPPRESSION
Presenter: Monica Gandhi, UCSF
 
Date: Tuesday, 2/21
Time: 2:30-4:00pm PT
 
Session: Poster Session- B7 LONG COVID
Title: PS 282: PLASMA-BASED ANTIGEN PERSISTENCE IN THE POST-ACUTE PHASE OF SARS-CoV-2 INFECTION
Presenter: Michael Peluso, UCSF
 
Session: Poster Session- E4 HIV RESERVOIRS IN CELLS AND TISSUES
Title: PS 421: T-TRACE ENABLES SINGLE-CELL MULTI-OMICS ANALYSIS OF HIV RESERVOIR CELLS FROM TISSUES
Presenter: Julie Frouard, Gladstone Institutes
 
Session: Poster Session- E6 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND
Title: PS 435: REBOUND DYNAMICS FOLLOWING IMMUNOTHERAPYWITH AN HIV VACCINE, TLR9 AGONIST, AND bNAb
Presenter: Michael Peluso, UCSF
 
Session: Poster Session- H1 LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING?
Title: PS 518: HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION
Presenter: Monica Gandhi, UCSF
 
Session: Poster Session- M2 METABOLIC COMPLICATIONS
Title: PS 679: ASSOCIATION OF SEX HORMONES WITH INCIDENT DIABETES IN WOMEN WITH AND WITHOUT HIV
Presenter: Rebecca Abelman, UCSF
 
Session: Poster Session- O3 STRATEGIES FOR OPTIMIZING TB TREATMENT AND PREVENTIVE THERAPY
Title: PS 752: LINEZOLID REACHES TARGET SITE IN PATIENTS WITH TB MENINGITIS AND HIV COINFECTION
Presenter: Rob van Wijk, UCSF
 
Session: Poster Session- O3 STRATEGIES FOR OPTIMIZING TB TREATMENT AND PREVENTIVE THERAPY
Title: PS 753: PREDICTIVE VALIDITY OF POPULATION MODELS FOR LINEZOLID EXPOSURE AND TOXICITY IN ZeNIX
Presenter: Marjorie Imperial, UCSF
 
Poster Session-R5 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION
Title: PS 864 NOT GETTING TO ZERO HIV FOR PEOPLE WHO INJECT DRUGS
Presenter: Bow Suprasert
 
Session: Poster Session- T2 DISPARITIES AND SOCIAL CONTEXT FOR HIV TESTING
Title: PS 937: OVER-AND UNDER-REPORTING IN HIV TESTING, STATUS, AND TREATMENT IN RURAL SOUTH AFRICA
Presenter: Hannah Leslie, UCSF
 
Session: Poster Session- V3 OPTIMIZING PrEP ROLLOUT
Title: PS 975: RANDOMIZED TRIAL OF DYNAMIC CHOICE PREVENTION AT AN OUTPATIENT DEPARTMENT IN EAST AFRICA
Presenter: Catherine Koss, UCSF
 
Session: Poster Session- W2 SARS-CoV-2 VACCINE STRATEGIES
Title: PS 1011: PREVALENCE AND CORRELATES OF SARS-CoV-2 VACCINE - HESITANCY AMONG US PEOPLE WITH HIV
Presenter: Matthew Spinelli, UCSF
 
Session: Poster Session- Y06 LONG-ACTING ART
Title: PS 1055: IDENTIFYING PREFERRED PROGRAM DELIVERY ATTRIBUTES FOR LONG-ACTING INJECTABLE ART
Presenter: Jose Gutierrez, UCSF
 
Session: Poster Session- Y14 COVID-19 EFFECT ON HIV SERVICES AND OUTCOMES
Title: PS 1094: VIRAL SUPPRESSION TRAJECTORIES DESTABILIZED AFTER - COVID-19 AMONG US PEOPLE WITH HIV
Presenter: Matthew Spinelli, UCSF
 
Date: Wednesday, 2/22
Time: 2:30-4:00pm PT
 
Session: Poster Session- A3 VIRUS REPRODUCTION
Title: PS 235: THERAPEUTIC INTERFERING PARTICLES (TIPS): ESCAPE- RESISTANT ANTIVIRAL FOR SARS-CoV-2
Presenter: Sonali Chaturvedi, Gladstone Institutes
 
Session: Poster Session- E3 IMMUNE PRESSURE ON THE HIV RESERVOIR
Title: PS 408: IMMUNE FEATURES ASSOCIATED WITH HIGHERT-CELL RESPONSES TO AN HIVTHERAPEUTICVACCINE
Presenter: Lily Zemelko, UCSF
 
Session: Poster Session- E3 IMMUNE PRESSURE ON THE HIV RESERVOIR
Title: PS 408: IMPACT OF SARS-CoV-2-MEDIATED CD4 T-CELL ACTIVATION AND HIV DNA PERSISTANCE IN VIVO
Presenter: Tyler-Marie Deveau, UCSF
 
Session: Poster Session- L4 INFLAMMATION AND CARDIOVASCULAR DISEASE
Title: PS 666: EXERCISE CAPACITY IS REDUCED IN HIV INDEPENDENT OF SARS CoV-2 INFECTION
Presenter: Matthew Durstenfeld, UCSF
 
Session: Poster Session- R7 FACTORS AFFECTING OUTCOMES FOR PEOPLE LIVING WITH HIV
Title: PS 883: RANDOMIZED TRIAL OF BRIEF ALCOHOL INTERVENTION FOR VIRAL SUPPRESSION AND ALCOHOL USE
Presenter: Sarah Puryear, UCSF
 
Poster Session-V4 PrEP USE IN SPECIAL POPULATIONS
Title: PS 983 NO IMPROVEMENT IN PREEXPOSURE PROPHYLAXIS USE AMONG PWID
Presenter: Morando Tate
External Link
CROI 2023 Program Guide